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Purpose: To investigate the effect of oral consumption of magnesium on the memory and pain 
sensation of diabetic rats.   
Methods: A total of 48 rats were divided into four groups - untreated control, untreated diabetic, 
magnesium-treated control and magnesium-treated diabetic. Plasma magnesium and glucose 
concentrations were measured after induction of diabetes with streptozotocin (STZ; 60 mg/kg). Four 
weeks after the administration of oral magnesium (10 g/L, MgSO4), the animals were subjected to 
passive avoidance test whereby latency time (LT) was assessed. This was followed by formalin test 
which entailed the determination of licking and flinching scores  
Results: Increased level of glucose and decreased concentration of magnesium in untreated diabetic 
group compared to untreated control group (p < 0.001) were observed. There was also a significant 
reduction in mean LT of untreated diabetic group (p < 0.001) as indicated by the increased number of 
animals that entered the dark compartment. Plasma glucose and magnesium levels in magnesium 
treated diabetic rats returned to normal 4 weeks after oral magnesium consumption. There was no 
significant change in mean total pain score despite elevated licking in diabetic animals after oral 
magnesium consumption. Significant elevation of flinching scores of untreated diabetic rats was 
observed in the last 20 min of the 2nd chronic phase, compared with the untreated control group. 
Conclusion: It seems that magnesium treatment either restores rat memory performance that is 
impaired by diabetes or that it affects the aversive responses evoked by electrical shock.  
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INTRODUCTION 
 
There are several theories regarding the 
pathology and cognitive impairment in 
individuals with diabetes [1-2]. The pathways 
through which the disease affects on 
cognitive function are abnormality in glucose 
metabolism and formation of advanced 
glycation end products [3-4]. Thus, any 
change in glucose concentrations can affect 
cognitive function. From a mechanistic 
standpoint, it is difficult to discern whether the 
main mechanism relating type II diabetes to 
cognitive impairment is linked to glycemia, a 
component of the metabolic syndrome (e.g., 
hypertension), insulin resistance, or factors 
specifically related to adipose tissue. The 
answer could be that there is an aggregate 
effect of all the components on lifespan [5].  
 
Occurrence of diabetes is a major risk factor 
for developing senile dementia which is 
regarded as one of the clinical signs of 
Alzheimer disease [6]. There are inadequate 
reports in the literature that associate 
diabetes and its effects on central nervous 
system and pain. However, one study has 
discussed the effect of diabetes on behavior, 
memory and learning [7]. Pain caused by 
peripheral nerve neuropathy is also one of 
the major clinical complaints described by 
patients with diabetes, and this affects the 
quality life of those concerned. Thus, 
alleviation of pain in these patients is of prime 
importance [8]. The results of a recent study 
have shown that high blood sugar is main 
causes of painful neuropathy caused by 
induced toxicity in peripheral nervous system 
[9].It seems that magnesium is a factor in the 
pathogenesis of diabetes as magnesium 
deficiency has been observed among 25 – 38 
% of diabetic patients, in particular among 
those without an appropriate metabolic 
control [7]. This element modulates glucose 
transport across the membranes and is 
considered an important co-factor in 
enzymatic systems such as glucose oxidation 
[10]. The association between diabetes and 
low magnesium level is well understood and 
it is known that low magnesium diet leads to 
impaired insulin secretion and action [11] and 
that magnesium supplementation has been 
shown to prevent fructose-induced insulin 
resistance and lowers the incidence of type II 
diabetes [12,13]. In addition, the effect of oral 
consumption of magnesium on glucose 
control and improving insulin sensitivity is 
well-documented [14]. There is an inverse 
correlation between the magnesium 
absorption and diabetes and hence the 
diabetic patients are recommended to 
consume foods rich in magnesium such as 
cereals and green vegetables [15].  
 
Therefore, the aim of this study was to 
assess memory performance and pain 
sensation in diabetic animals following 
consumption of oral magnesium using 







Magnesium sulfate (MgSO4) was provided 
from Merck Company and used as aqueous 
solution. Streptozotocin (STZ) was obtained 
from Sigma in lyophilized form as (1 g vials).  
 
Animals and treatments 
 
A total of 48 male rats locally produced in 
Naval Medical Research Institute (Razi, Co. 
Iran), weighing 180 - 250 g were used. The 
animals were kept in 12 h light/12 h dark 
cycles at 22 ± 0.5 °C and freely received 
water and their normal  food. All the 
experiments were approved by the Ethical 
Review Committee (Project no. 5167, Qazvin 
University of Medical Sciences) and were 
carried out according to the Ethical 
Guidelines for the Investigations of 
Experimental Pain in Conscious Animals 
issued by the International Association for the 
Pain Study (16).   
 
The animals were divided equally into 4 
groups, as follows: normal control, diabetic, 
magnesium-treated normal, and magnesium-
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treated diabetic (MgSO4, 10 g/L of water). 
Oral magnesium administration in both 
magnesium-treated normal and diabetic 
groups continued for 4 weeks while the other 
two groups (normal control and diabetic 
groups) received water only. Induction of 
diabetes in diabetic groups was 
accomplished by a single intraperitoneal 
injection of STZ (60 mg/kg). One week after 
STZ injection, the animals with a minimum 
plasma glucose level of 250 mg/dl were 
considered as diabetic. The glucose 
concentration were measured with 
enzymatic-calorimetric kit (Zistshimi, 
Iran).Diabetic rats were given oral 
magnesium solution (10 g/L, MgSO4) in their 
drinking water for four weeks.  
 
Measurement of plasma magnesium and 
glucose levels  
 
Development of diabetes following the 
administration of STZ was confirmed by 
measuring the blood glucose and magnesium 
level using the enzyme-based commercial 
kits(Zistshimi, Iran).. Plasma glucose and 
magnesium concentrations were measured 
spectrophotometrically (Rayleigh UV-2100 
Spectrophotometer, China) at 520 and 510 
nm wave lengths, respectively. 
 
Passive-avoidance memory test 
 
Using a shuttle box, passive-avoidance 
learning test was applied to measure memory 
and passive-avoidance response. The 
learning phase was carried out in four stages 
after a 5-min adaptation period in the shuttle 
box. A time interval of 1 h was considered 
between the stages of the learning phase, 
while the waiting time for each animal to 
enter the dark compartment was 5 min. 
Animals with LT higher than 5 min were 
excluded from the study. At the 4th stage of 
the learning phase and following arrival of the 
animal into the dark compartment, an 
electrical current of 1 mA intensity was 
applied to the animal footpads. The electrical 
shock was exerted within the last 5 seconds 
of the second minute using a shock generator 
instrument which caused the animal to jump 
and this was taken as proof of delivery of 
shock. Shortly after the delivery of shock, the 
guillotined door was opened to let the 
shocked animal enter the light compartment 
followed by removal of the animal from the 
instrument [17]. The delay time for animals to 
enter from the light to dark compartments 
was considered as latency time (LT). Once 
the 4th stage of learning was completed, data 
acquisition from the passive-avoidance test 
as a short-term performance criterion was 
carried out by determining LT at different time 
intervals (1, 6, 24 and 48 h,, and then 1 and 2 
weeks) after shock induction. The passive-
avoidance learning test was performed 
following magnesium treatment or induction 
of diabetes. 
 
Measurement of pain scores (Formalin 
test) 
 
Pain assessment was determined by 
Formalin test. This test was accomplished by 
injection of 50 µl of 2.5 % formalin solution as 
a chemical noxious stimulus into the animal 
planar hind paw followed by recording of the 
associated flinching and licking scores. The 
test was performed after the final session of 




Statistical analyses were performed using 
SPSS (version 16). Differences between the 
four groups were analyzed using Student t-
test and one-way analysis of variance 
(ANOVA) while multiple comparisons 
between the groups was carried out with 
Tukey as post-hoc test. A probability value of 




Effect of magnesium administration on 
plasma glucose 
 
Mean serum glucose data are presented in 
Figure 1. Plasma glucose level at baseline 
and after 4 weeks for the untreated control 
Sarreshtehdari et al 
Trop J Pharm Res, December 2012;11 (6): 950 
group was 107.0 ± 12.0 and 124.5 ± 6.6 
mg/dl, respectively (p = 0.08). Similarly, the 
glucose concentration of untreated diabetic 
group at baseline and after 4 weeks was 
478.0 ± 89.0 and 479.0 ± 63.0 mg/dl, 
respectively (p = 0.24). In magnesium-treated 
control group, plasma glucose concentration 
was 126.6 ± 18.7 mg/dl at the beginning of 
the learning phase and 119.0 ± 12.5 mg/dl at 
the end of 4 weeks (p = 0.13). Mean mean 
plasma glucose level in magnesium-treated 
diabetic group after 4 weeks was 140.5 ± 
24.1 mg/dl and the difference between this 
group and the untreated diabetic group was 
significant (p < 0.001). There was no 
significant difference between the 
magnesium-treated diabetic and untreated 
control groups.  
 
 
Figure 1: Influence of oral magnesium 
administration on plasma glucose concentration 
measured at time zero (transparent bars), after 4 
weeks (dark bars), and 4 weeks following 
magnesium treatment (gray bars) in comparison 
with untreated diabetic rats; *p < 0.001. 
 
Effect of magnesium administration on 
plasma magnesium  
 
The plasma magnesium level of untreated 
control was significantly (p < 0.001) 
decreased more than that of the untreated 
diabetic group (2.47 ± 0.18 versus 1.65 ± 
0.15 mg/dl). Furthermore, plasma 
magnesium concentration in magnesium-
treated diabetic group (2.44 ± 0.23 mg/dl) 
significantly increased compared with 
untreated diabetic group after 4 weeks of 
magnesium treatment. However, there was 
no significant difference between the plasma 
magnesium levels of untreated control, 
magnesium-treated control, and untreated 
diabetic groups (p = 0.32). 
  
Table 1:  Latency time (LT) and frequency of 
animal entry into the dark compartment in passive 











n = number of animals entered the dark compartment of 
shuttle box (mean ±SEM), n = 12); *= Statistical 
significance (p < 0.001) for latency time (LT) values, 
compared to untreated control group 
 
Effect of magnesium administration on 
passive avoidance memory 
 
Evaluation of short-term memory was 
determined after 1, 6, 24 and 48 h, then 1 
and 2 weeks following the 4th phase of 
learning and application of electrical shock. 
The results are presented in Table 1. Among 
the untreated diabetic group, mean LT was 
significantly lower than that of the untreated 
control group (p < 0.001). In addition, the 
frequency of entries in untreated diabetic 
control group was higher than those in 
untreated control group. Nevertheless, LT for 
both magnesium-treated control and 
magnesium-treated diabetic groups was 
insignificant compared to that of the 
untreated control.  
 
Effect of magnesium administration on 
pain  
 
The results of the evaluation of pain based on 
the formalin test (licking and flinching pain 
models) are depicted in Figure 2. The pain 
score for licking response, both during the 
acute (first 10 min) and chronic phases (15 - 
60 min) for the magnesium-treated diabetic 
group was significantly (p < 0.05) than that for 
















 1 h  2.8 ±162.0 47.7 ±1.9*** - 147.5± 2.4  
 6 h  1.8 ±158.0 45.0 ±4.9*** 167.0±1.4  151.0 ±0.9  
 24 h  0.8± 145.0 38.0 ±5.7*** 159.0 ±1.8 160.0± 2.4  
 48 h  135.0± 6.41   41.8 ±8.2***  152.1±4.0  152.5 ±2.4 
 1 week  122.7 ±10.0   35.0±7.6*** 151.5± 9.3  120.0±18.4  
 2 week 112.0 ±11.3  36.2 ±10.5*** 133.0±4.8  91.3± 9.4  
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Figure 2: Effect of oral magnesium administration 
in formalin-induced biphasic pain model (Error 
bars denote SEM). Key: No. of hindpaw licks in 
untreated control (), untreated diabetic (), 
magnesium-treated control (), and magnesium-
treated diabetic (▲) groups; *= untreated diabetic 
in comparison with magnesium-treated diabetic 
groups; += untreated control in comparison with  
magnesium-treated control groups. *p < 0.05; **p < 
0.01, and ***p < 0.001 
 
Magnesium-treated control showed more 
licking than untreated control in the final 20 
min of chronic pain phase (Figure 2).  
 
However, in the flinching response pain 
model (Figure 3), significantly higher scores 
were recorded for untreated diabetic and 
magnesium-treated groups. The flinching 
scores of untreated diabetic group increased 
significantly, compared with untreated control 
group. 
 
The total scores for both acute and chronic 
phases in magnesium-treated diabetic and 
magnesium-treated control groups were not 
significantly different from those of the 
untreated groups. However, as Figure 4 
shows, the total scores for the chronic phase 
in the magnesium-treated diabetic and 
untreated diabetic groups were higher than 
those of magnesium-treated control and 




Figure 3: Effect of oral magnesium administration 
in formalin-induced biphasic pain model (Error 
bars denote SEM). No. of hindpaw flinches in 
untreated control (), untreated diabetic (), 
magnesium-treated control (), and magnesium-
treated diabetic groups (▲). *= untreated diabetic 
in comparison with  magnesium-treated diabetic 
groups; += untreated control in comparison with  
magnesium-treated control groups; &= untreated 
diabetic in comparison with  untreated control 




Figure 4: Mean total scores for chronic pain phase 




Since total pain score in chronic pain phase 
was higher for untreated and magnesium-
treated diabetic groups than for untreated 
and magnesium-treated control groups, it can 
be said that the hyperalgesia produced in the 
two diabetic groups was induced by elevated 
blood glucose. Furthermore, the aversive 
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response in magnesium-treated diabetic 
group; evoked by electrical shock, returned to 
its normal range. The higher LT values and 
the low number of animals entered the dark 
compartment for the magnesium-treated 
control group may be attributed to the 
increased sensitivity to electrical shock, 
leading to a mild alteration in aversive 
response. However, this assumption needs 
further investigation since the pain induced 
by formalin is due to a chemical noxious 
stimulus which is different from that induced 
by an electrical shock.   
 
Magnesium reduction occurs in both type-1 
and type-2 diabetes especially when toxins 
such as streptozotocin with known strong 
diabetogenic and pathologic effects (e.g., 
hypertension) are used [18-19]. Furthermore, 
it has been reported that continuous high 
serum glucose level is often accompanied by 
reduced magnesium serum level and that 
there is a correlation between magnesium 
deficiency, on the one hand, and insulin 
resistance and decreased insulin secretion in 
diabetic patients [20-21]. Many physicians 
have suggested daily administration of 300 - 
400 mg of magnesium in diabetic patients 
having normal kidney function [15].  The 
restoration of plasma glucose concentration 
to the same level as that of control indicates 
that the mechanism is probably to that 
through which glucose transfer within 
membranes is modulated by magnesium and 
is considered an important cofactor in 
enzymatic systems such as glucose oxidation 
[14].   
 
The present study revealed differences 
between the animal groups with regard to 
memory processing and function. Decrease 
in the latency time (LT) of the diabetic 
animals as well as the increase in the number 
of animals that entered the dark compartment 
are indicative of poor cognitive function 
induced by diabetes; this is consistent with 
earlier findings [1-2]. This is buttressed by 
entry of animals into the dark compartment 2 
weeks later, indicating disappearance of 
memory associated with electrical shock. 
After four weeks of magnesium treatment, 
there was a significant decrease in the 
plasma glucose concentration and 
improvement in cognitive performance of the 
animals with experimentally-induced 
diabetes. 
 
As reported by Obrosova, peripheral 
neuropathy is the most important and 
generalized complications of diabetic patients 
with a frequency of up to 60 % [22]. 
Neuropathic pain is a chronic pain manifested 
by a change in pain nociception, accelerated 
feeling of pain in response to painful stimuli 
(hyperalgesia), and abnormal painful 
sensitivity to those stimuli that were not 
painful earlier (allodynia) [23]. In an acute 
thermal test for pain processing, which 
involved measurement of pain threshold 
through tail flick latency, it was shown that 
oral magnesium administration prevents 
thermal hyperalgesia induced by diabetes in 
rats [24]. In agreement with our study, the 
findings of a recent report showed a 
significant reduction in plasma magnesium 
levels in diabetic animals. However, this 
condition was restored by 8-week oral 
magnesium administration, correcting the 
thermal pain threshold and plasma glucose 
level [24].  
 
Formalin-induced pain behavior is considered 
a valid model of clinical pain (i.e., chronic 
pain experienced by man). The period of 
pain-induced behavior following 
subcutaneous injection of dilute formalin into 
rat hindpaw is divided into two phases, 
namely, an acute phase which is a temporary 
provocative response lasting approximately 2 
- 5 min and a chronic phase which continues 
for at least 25 - 40 min, depending on the 
concentration of formalin used [25]. In the 
present study, the biphasic model of pain was 
clearly differentiated and recognized through 
licking and flinching modalities of pain. In this 
pain model, diabetic animals with no 
magnesium consumption showed an 
aggravated pain on both scores compared to 
control group, indicating the effects of 
neuropathy and hyperglycemia. In addition, 
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both diabetic and normal groups treated with 
magnesium for 4 weeks showeded 
hyperalgesia, unlike groups without 
magnesium treatment. It seems that the 
higher magnesium dose used in these 
animals is the likely cause of the 
hyperalgesia. It has been reported that an 
inverse correlation between magnesium 
absorption and diabetes exists, which is why 
diabetic patients are advised to consume 
foodstuffs rich in magnesium, such as cereals 




Based on the findings of the present study, it 
is clear that while oral administration of 
magnesium causes a significant decrease in 
plasma glucose, it considerably increases 
plasma magnesium levels in diabetic 
animals. Furthermore, long-term consumption 
of magnesium leads to the increased ability 
of diabetic animals to store information in 
memory space as well as increase their 
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